Coronavirus disease 2019
From Wikipedia the free encyclopedia
|Coronavirus disease 2019|
|Symptoms||Fever, cough, fatigue, shortness of breath, loss of taste or smell; sometimes no symptoms at all|
|Complications||Pneumonia, viral sepsis, acute respiratory distress syndrome, kidney failure, cytokine release syndrome|
|Usual onset||2–14 days (typically 5) from infection|
|Duration||5 days to 6+ months known|
|Causes||Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)|
|Diagnostic method||rRT-PCR testing, CT scan|
|Prevention||Hand washing, face coverings, quarantine, social distancing|
|Treatment||Symptomatic and supportive|
|Frequency||40,425,663 confirmed cases|
|Part of a series on the|
Coronavirus disease 2019 (COVID-19) is a contagious respiratory and vascular (blood vessel) disease. It is caused by becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a specific type of coronavirus. Common symptoms include fever, cough, fatigue, shortness of breath or breathing difficulties, and loss of smell and taste. The incubation period, which is the time between becoming infected with the virus and showing symptoms, may range from one to fourteen days. While most people have mild symptoms, some people develop acute respiratory distress syndrome (ARDS) possibly precipitated by cytokine storm, multi-organ failure, septic shock, and blood clots. Longer-term damage to organs (in particular lungs and heart) has been observed, and there is concern about a significant number of patients who have recovered from the acute phase of the disease but continue to experience a range of effects—including severe fatigue, memory loss and other cognitive issues, low grade fever, muscle weakness, breathlessness, and other symptoms—for months afterwards.
COVID-19 spreads most often when people are physically close.[a] It spreads very easily and sustainably through the air, primarily via small droplets or aerosols, as an infected person breathes, coughs, sneezes, sings, or talks. It may also be transmitted via contaminated surfaces, although this has not been conclusively demonstrated. Airborne transmission from aerosol formation is suspected to be the main mode of transmission. It can spread from an infected person for up to two days before they display symptoms, and from people who are asymptomatic. People remain infectious for seven to twelve days in moderate cases, and up to two weeks in severe cases. The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab.
Recommended measures to prevent infection include frequent social distancing, quarantine, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or cloth face coverings has been recommended by health officials in public settings to minimise the risk of transmissions, with some authorities requiring their use in certain settings, such as on public transport and in shops.
There are no proven vaccines or specific treatments for COVID-19 yet, though several are in development. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures. The World Health Organization (WHO) declared the COVID-19 outbreak a pandemic on 11 March 2020.
Signs and symptoms
Symptoms of COVID-19 can be relatively non-specific; the two most common symptoms are fever (88 percent) and dry cough (68 percent). Among those who develop symptoms, approximately one in five may become more seriously ill and have difficulty breathing. Emergency symptoms include difficulty breathing, persistent chest pain or pressure, sudden confusion, difficulty waking, and bluish face or lips; immediate medical attention is advised if these symptoms are present. Further development of the disease can lead to complications including pneumonia, acute respiratory distress syndrome, sepsis, septic shock, and kidney failure.As is common with infections, there is a delay, known as the incubation period, between the moment a person first becomes infected and the appearance of the first symptoms. The median incubation period for COVID-19 is four to five days. Most symptomatic people experience symptoms within two to seven days after exposure, and almost all symptomatic people will experience one or more symptoms before day twelve.
COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strain.
COVID-19 is thought to spread mainly through the respiratory route (both droplet and aerosol), after an infected person coughs, sneezes, sings, talks or breathes. A new infection occurs when those droplets get into the mouth, nose or eyes of other people who are in close contact[b] with the infected person. The respiratory droplets evaporate into aerosols, which remain suspended in the air for longer periods of time, causing airborne transmission particularly in crowded and inadequately ventilated indoor spaces, such as restaurants, nightclubs or choirs. It also can occur in the healthcare setting, with certain aerosol-generating medical procedures performed on COVID-19 patients.
It may be possible that a person can get COVID-19 through indirect contact by touching a contaminated surface or object, and then touching their own mouth, nose, or possibly their eyes, though this is not thought to be the main way the virus spreads. Kissing, physical intimacy and other forms of direct contact can easily transmit the virus and thus lead to COVID-19 in people exposed to such contact. There currently is no significant evidence of COVID-19 virus transmission through feces, urine, breast milk, food, wastewater, drinking water, animal disease vectors, or from mother to baby during pregnancy, although research is ongoing and caution is advised.[needs update]
Social distancing and the wearing of cloth face masks, surgical masks, respirators, or other face coverings are controls for droplet transmission. Transmission may be decreased indoors with well maintained heating and ventilation systems to maintain good air circulation and increase the use of outdoor air.
The number of people generally infected by one infected person varies; as of September 2020 it was estimated that one infected person will on average infect between two and three other people. This is more infectious than influenza, but less so than measles. It often spreads in clusters, where infections can be traced back to an index case or geographical location. There is a major role of "super-spreading events", where many people are infected by one person.It can transmit when people are symptomatic, also for up to two days prior to developing symptoms, and even if a person never shows symptoms. People remain infectious in moderate cases for 7-12 days, and up to two weeks in severe cases. In October 2020, medical scientists reported evidence of reinfection in one patient.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan. All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature.
SARS-CoV-2 is closely related to the original SARS-CoV. It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13). The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S).The M protein of SARS-CoV-2 is 98.6% similar to the M protein of bat SARS-CoV, maintains 98.2% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only 38% with the M protein of MERS-CoV. In silico analyses showed that the M protein of SARS-CoV-2 has a triple helix bundle, forms a single 3-transmembrane domain, and is homologous to the prokaryotic sugar transport protein SemiSWEET.
COVID-19 can affect the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs). The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell. The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested decreasing ACE2 activity might be protective, though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective. As the alveolar disease progresses, respiratory failure might develop and death may follow.
SARS-CoV-2 may also cause respiratory failure through affecting the brain stem as other coronaviruses have been found to invade the Central nervous system (CNS). While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain.
The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium as well as endothelial cells and enterocytes of the small intestine.
The virus can cause acute myocardial injury and chronic damage to the cardiovascular system. An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China, and is more frequent in severe disease. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. ACE2 receptors are highly expressed in the heart and are involved in heart function. A high incidence of thrombosis and venous thromboembolism have been found in ICU patients with COVID-19 infections, and may be related to poor prognosis. Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.
Another common cause of death is complications related to the kidneys. Early reports show that up to 30% of hospitalized patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.
Autopsies of people who died of COVID-19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.
Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID-19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), Macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.
Additionally, people with COVID-19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.
Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID-19 patients. Lymphocytic infiltrates have also been reported at autopsy.
The WHO has published several testing protocols for the disease. The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR). The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. Results are generally available within a few hours to two days. Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value. Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus. As of 4 April 2020[update], antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used. Antibody tests may be most accurate 2–3 weeks after a person's symptoms start. The Chinese experience with testing has shown the accuracy is only 60 to 70%. The US Food and Drug Administration (FDA) approved the first point-of-care test on 21 March 2020 for use at the end of that month. The absence or presence of COVID-19 signs and symptoms alone is not reliable enough for an accurate diagnosis. Different clinical scores were created based on symptoms, laboratory parameters and imaging to determine patients with probable SARS-CoV-2 infection or more severe stages of COVID-19.
Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count.
A study asked hospitalised COVID-19 patients to cough into a sterile container, thus producing a saliva sample, and detected the virus in eleven of twelve patients using RT-PCR. This technique has the potential of being quicker than a swab and involving less risk to health care workers (collection at home or in the car).
Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.  Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection. Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.
In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.
The main pathological findings at autopsy are:
- Macroscopy: pericarditis, lung consolidation and pulmonary oedema
- Lung findings:
- minor serous exudation, minor fibrin exudation
- pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
- diffuse alveolar damage (DAD) with diffuse alveolar exudates. DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
- organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
- plasmocytosis in BAL
- Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
- Liver: microvesicular steatosis
A COVID-19 vaccine is not expected until 2021 at the earliest. The US National Institutes of Health guidelines do not recommend any medication for prevention of COVID-19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial. Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID-19 is trying to decrease and delay the epidemic peak, known as "flattening the curve". This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.
Preventive measures to reduce the chances of infection include staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands. Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.
Personal protective equipment
For health care professionals who may come into contact with COVID-19 positive bodily fluids, using personal protective coverings on exposed body parts improves protection from the virus. Breathable personal protective equipment[clarification needed] improves user-satisfaction and may offer a similar level of protection from the virus. In addition, adding tabs and other modifications to the protective equipment may reduce the risk of contamination during donning and doffing (putting on and taking off the equipment). Implementing an evidence-based donning and doffing protocol such as a one-step glove and gown removal technique, giving oral instructions while donning and doffing, double gloving, and the use of glove disinfection may also improve protection for health care professionals.
The World Health Organization (WHO) and most government health agencies (such as the US Centers for Disease Control and Prevention (CDC), the UK National Health Service (NHS), or the New Zealand Ministry of Health) recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain. This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing. Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus.
Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease.
Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings. Distancing guidelines also include that people stay at least 2 metres (6.6 ft) apart. After the implementation of social distancing and stay-at-home orders, many regions have been able to sustain an effective transmission rate ("Rt") of less than one, meaning the disease is in remission in those areas.
Hand-washing and hygiene
When not wearing a mask, the CDC, WHO, and NHS recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. The WHO also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose. The CDC recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available. For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.
Sanitizing of frequently touched surfaces is also recommended or required by regulation for businesses and public facilities; the United States Environmental Protection Agency maintains a list of products expected to be effective.
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs. The CDC recommends those who suspect they carry the virus wear a simple face mask. Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.[needs update] Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity. Supportive treatments may be useful in those with mild symptoms at the early stage of infection.
The WHO, the Chinese National Health Commission, and the United States' National Institutes of Health have published recommendations for taking care of people who are hospitalised with COVID-19. Intensivists and pulmonologists in the US have compiled treatment recommendations from various agencies into a free resource, the IBCC.
The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. The Italian Istituto Superiore di Sanità reported that the median time between the onset of symptoms and death was twelve days, with seven being spent hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death.
According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers, air pollution is similarly associated with risk factors, and pre-existing heart and lung diseases and also obesity contributes to an increased health risk of COVID-19.
It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2. One research that looked into the COVID-19 infections in hospitalized kidney transplant recipients found a mortality rate of 11%.
Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years. They are likely to have milder symptoms and a lower chance of severe disease than adults.
A European multinational study of hospitalized children published in The Lancet on 25 June 2020 found that about 8% of children admitted to a hospital needed intensive care. Four of those 582 children (0.7%) died, but the actual mortality rate could be "substantially lower" since milder cases that did not seek medical help were not included in the study.
Mortality rates are highly correlated to age. In those younger than 50 years the risk of death is less than 0.5%, while in those older than 70 it is more than 8%. According to a CDC analysis, the risk of death by age groups in the United States is 0.003%, 0.02%; 0.5% and 5.4% for the age groups 0–19, 20–49, 50–69, and 70 or over, respectively.
Genetics also plays an important role in the ability to fight off the disease. For instance, those that do not produce detectable type I-interferons may get much sicker from COVID-19. Genetic screening is able to detect interferon effector genes.
Pregnant women may be at higher risk of severe COVID-19 infection based on data from other similar viruses, like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), but data for COVID-19 is lacking.
|Argentina as of 7 May||0.0||0.0||0.1||0.4||1.3||3.6||12.9||18.8||28.4|
|Australia as of 4 June||0.0||0.0||0.0||0.0||0.1||0.2||1.1||4.1||18.1||40.8|
|Canada as of 3 June||0.0||0.1||0.7||11.2||30.7|
|Alberta as of 3 June||0.0||0.0||0.1||0.1||0.1||0.2||1.9||11.9||30.8|
|Br. Columbia as of 2 June||0.0||0.0||0.0||0.0||0.5||0.8||4.6||12.3||33.8||33.6|
|Ontario as of 3 June||0.0||0.0||0.1||0.2||0.5||1.5||5.6||17.7||26.0||33.3|
|Quebec as of 2 June||0.0||0.1||0.1||0.2||1.1||6.1||21.4||30.4||36.1|
|Chile as of 31 May||0.1||0.3||0.7||2.3||7.7||15.6|
|China as of 11 February||0.0||0.2||0.2||0.2||0.4||1.3||3.6||8.0||14.8|
|Colombia as of 3 June||0.3||0.0||0.2||0.5||1.6||3.4||9.4||18.1||25.6||35.1|
|Denmark as of 4 June||0.2||4.1||16.5||28.1||48.2|
|Finland as of 4 June||0.0||0.0||<0.4||<0.4||<0.5||0.8||3.8||18.1||42.3|
|Germany as of 5 June||0.0||0.0||0.1||1.9||19.7||31.0|
|Bavaria as of 5 June||0.0||0.0||0.1||0.1||0.2||0.9||5.4||15.8||28.0||35.8|
|Israel as of 3 May||0.0||0.0||0.0||0.9||0.9||3.1||9.7||22.9||30.8||31.3|
|Italy as of 3 June||0.3||0.0||0.1||0.3||0.9||2.7||10.6||25.9||32.4||29.9|
|Japan as of 7 May||0.0||0.0||0.0||0.1||0.3||0.6||2.5||6.8||14.8|
|Mexico as of 3 June||3.3||0.6||1.2||2.9||7.5||15.0||25.3||33.7||40.3||40.6|
|Netherlands as of 3 June||0.0||0.2||0.1||0.3||0.5||1.7||8.1||25.6||33.3||34.5|
|Norway as of 4 June||0.0||0.0||0.0||0.0||0.3||0.4||2.2||9.0||22.7||57.0|
|Philippines as of 4 June||1.6||0.9||0.5||0.8||2.4||5.5||13.2||20.9||31.5|
|Portugal as of 3 June||0.0||0.0||0.0||0.0||0.3||1.3||3.6||10.5||21.2|
|South Africa as of 28 May||0.3||0.1||0.1||0.4||1.1||3.8||9.2||15.0||12.3|
|South Korea as of 17 July||0.0||0.0||0.0||0.1||0.2||0.6||2.3||9.5||25.2|
|Spain as of 29 May||0.3||0.2||0.2||0.3||0.6||1.4||5.0||14.3||20.8||21.7|
|Sweden as of 5 June||0.5||0.0||0.2||0.2||0.6||1.7||6.6||23.4||35.6||40.3|
|Switzerland as of 4 June||0.6||0.0||0.0||0.1||0.1||0.6||3.4||11.6||28.2|
|Colorado as of 3 June||0.2||0.2||0.2||0.2||0.8||1.9||6.2||18.5||39.0|
|Connecticut as of 3 June||0.2||0.1||0.1||0.3||0.7||1.8||7.0||18.0||31.2|
|Georgia as of 3 June||0.0||0.1||0.5||0.9||2.0||6.1||13.2||22.0|
|Idaho as of 3 June||0.0||0.0||0.0||0.0||0.0||0.4||3.1||8.9||31.4|
|Indiana as of 3 June||0.1||0.1||0.2||0.6||1.8||7.3||17.1||30.2|
|Kentucky as of 20 May||0.0||0.0||0.0||0.2||0.5||1.9||5.9||14.2||29.1|
|Maryland as of 20 May||0.0||0.1||0.2||0.3||0.7||1.9||6.1||14.6||28.8|
|Massachusetts as of 20 May||0.0||0.0||0.1||0.1||0.4||1.5||5.2||16.8||28.9|
|Minnesota as of 13 May||0.0||0.0||0.0||0.1||0.3||1.6||5.4||26.9|
|Mississippi as of 19 May||0.0||0.1||0.5||0.9||2.1||8.1||16.1||19.4||27.2|
|Missouri as of 19 May||0.0||0.0||0.1||0.2||0.8||2.2||6.3||14.3||22.5|
|Nevada as of 20 May||0.0||0.3||0.3||0.4||1.7||2.6||7.7||22.3|
|N. Hampshire as of 12 May||0.0||0.0||0.4||0.0||1.2||0.0||2.2||12.0||21.2|
|Oregon as of 12 May||0.0||0.0||0.0||0.0||0.5||0.8||5.6||12.1||28.9|
|Texas as of 20 May||0.0||0.5||0.4||0.3||0.8||2.1||5.5||10.1||30.6|
|Virginia as of 19 May||0.0||0.0||0.0||0.1||0.4||1.0||4.4||12.9||24.9|
|Washington as of 10 May||0.0||0.2||1.3||9.8||31.2|
|Wisconsin as of 20 May||0.0||0.0||0.2||0.2||0.6||2.0||5.0||14.7||19.9||30.4|
Most of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. According to March data from the United States, 89% of those hospitalised had preexisting conditions. The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases. According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), ischemic heart disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).
Most critical respiratory comorbidities according to the CDC, are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis. Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse patient outcomes. When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms. COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.
Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions). Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal.
Some early studies  suggest between 1 in 5 and 1 in 10 people with COVID-19 will experience symptoms lasting longer than a month. A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath.
The immune response by humans to CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production, just as with most other infections. However, it remains unknown if the immunity is long-lasting in people who recover from the disease.[needs update] Cases in which recovery from COVID-19 was followed by positive tests for coronavirus at a later date have been reported. In some of these cases, the RNA from the first and second infections indicates a different strain of the virus. Some reinfection cases are believed to be lingering infection rather than reinfection, or false positives due to remaining, non-infectious RNA fragments. Some other coronaviruses circulating in people are capable of reinfection after roughly a year.
The virus is thought to be natural and has an animal origin, through spillover infection. The first known human infections were in Wuhan, Hubei, China. A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, reported the earliest date of onset of symptoms as 1 December 2019. Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019. Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020. According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. In May 2020, George Gao, the director of the Chinese Center for Disease Control and Prevention, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but it was not the site of the initial outbreak. Traces of the virus have been found in wastewater that was collected from Milan and Turin, Italy, on 18 December 2019.
There are several theories about where the first case (the so-called patient zero) originated. According to an unpublicised report from the Chinese government, the first case can be traced back to 17 November 2019; the person was a 55-year-old citizen in the Hubei province. There were four men and five women reported to be infected in November, but none of them were "patient zero". By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. The number of coronavirus cases in Hubei gradually increased, reaching 60 by 20 December and at least 266 by 31 December. On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus. A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December. On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. That evening, the Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause". Eight of these doctors, including Li Wenliang (punished on 3 January), were later admonished by the police for spreading false rumours, and another, Ai Fen, was reprimanded by her superiors for raising the alarm.
The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases—enough to trigger an investigation.
During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange. On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen. Later official data shows 6,174 people had already developed symptoms by then, and more may have been infected. A report in The Lancet on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential". On 30 January, the WHO declared the coronavirus a Public Health Emergency of International Concern. By this time, the outbreak spread by a factor of 100 to 200 times.
On 31 January 2020, Italy had its first confirmed cases, two tourists from China. As of 13 March 2020, the World Health Organization (WHO) considered Europe the active centre of the pandemic. On 19 March 2020, Italy overtook China as the country with the most deaths. By 26 March, the United States had overtaken China and Italy with the highest number of confirmed cases in the world. Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country. Retesting of prior samples found a person in France who had the virus on 27 December 2019 and a person in the United States who died from the disease on 6 February 2020.
On 11 June 2020, after 55 days without a locally transmitted case, Beijing reported the first COVID-19 case, followed by two more cases on 12 June. By 15 June 79 cases were officially confirmed. Most of these patients went to Xinfadi Wholesale Market.
Several measures are commonly used to quantify mortality. These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.
The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 2.8% (1,118,635/40,425,663) as of 20 October 2020. The number varies by region.
Other measures include the case fatality rate (CFR), which reflects the percentage of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percentage of infected individuals (diagnosed and undiagnosed) who die from a disease. These statistics are not time-bound and follow a specific population from infection through case resolution. Many academics have attempted to calculate these numbers for specific populations.
Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing. In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.
Infection fatality rate
Infection fatality rate or infection fatality ratio (IFR) is distinguished from case fatality rate (CFR). The CFR for a disease is the proportion of deaths from the disease compared to the total number of people diagnosed with the disease (within a certain period of time). The IFR, in contrast, is the proportion of deaths among all the infected individuals. IFR, unlike CFR, attempts to account for all asymptomatic and undiagnosed infections.
In February, the World Health Organization reported estimates of IFR between 0.3% and 1%. On 2 July, The WHO's Chief Scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%.
The CDC estimated for planning purposes that the IFR was 0.65% and that 40% of infected individuals are asymptomatic, suggesting a fatality rate among those who are symptomatic of 1.1% (.65/60) (as of 10 July). Studies incorporating data from broad serology testing in Europe show IFR estimates converging at approximately 0.5–1%. According to the University of Oxford Centre for Evidence-Based Medicine (CEBM), random antibody testing in Germany suggested a national IFR of 0.4% (0.1% to 0.9%).
Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. As of 10 July, in New York City, with a population of 8.4 million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID-19 (0.3% of the population). May antibody testing in New York City suggested an IFR of 0.9%. In Bergamo province, 0.6% of the population has died.
Early reviews of epidemiologic data showed greater impact of the pandemic and a higher mortality rate in men in China and Italy. The Chinese Center for Disease Control and Prevention reported the death rate was 2.8% for men and 1.7% for women. Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders. One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors. Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men. In Europe, 57% of the infected people were men and 72% of those died with COVID-19 were men. As of April 2020, the US government is not tracking sex-related data of COVID-19 infections. Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
|Percentage of infected people who are hospitalized|
|Percentage of hospitalized people who go to Intensive Care Unit|
|Percent of hospitalized people who die|
|Percent of infected people who die – infection fatality rate (IFR)|
|Numbers in parentheses are 95% credible intervals for the estimates.|
In the US, a greater proportion of deaths due to COVID-19 have occurred among African Americans. Structural factors that prevent African Americans from practicing social distancing include their concentration in crowded substandard housing and in "essential" occupations such as public transit and health care. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death. Similar issues affect Native American and Latino communities. According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults. The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water. Leaders have called for efforts to research and address the disparities.
Society and culture
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", with the disease sometimes called "Wuhan pneumonia". In the past, many diseases have been named after geographical locations, such as the Spanish flu, Middle East Respiratory Syndrome, and Zika virus.
In January 2020, the World Health Organization recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma.
The official names COVID-19 and SARS-CoV-2 were issued by the WHO on 11 February 2020. WHO chief Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
Humans appear to be capable of spreading the virus to some other animals. A domestic cat in Liège, Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive. Tigers and lions at the Bronx Zoo in New York, United States, tested positive for the virus and showed symptoms of COVID-19, including a dry cough and loss of appetite. Minks at two farms in the Netherlands also tested positive for COVID-19.
A study on domesticated animals inoculated with the virus found that cats and ferrets appear to be "highly susceptible" to the disease, while dogs appear to be less susceptible, with lower levels of viral replication. The study failed to find evidence of viral replication in pigs, ducks, and chickens.
As of August 2020, dozens of domestic cats and dogs had tested positive, though according to the U.S. CDC, there was no evidence they transmitted the virus to humans. CDC guidance recommends potentially infected people avoid close contact with pets.
No medication or vaccine other than remdesivir is approved with the specific indication to treat the disease. In Australia and the European Union, remdesivir (Veklury) is indicated for the treatment of COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen. International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers. In March, the World Health Organization initiated the "Solidarity Trial" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy. The World Health Organization suspended hydroxychloroquine from its global drug trials for COVID-19 treatments on 26 May 2020 due to safety concerns. It had previously enrolled 3,500 patients from 17 countries in the Solidarity Trial. France, Italy and Belgium also banned the use of hydroxychloroquine as a COVID-19 treatment.
Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission, diagnosis and prognosis of infection, estimation of the impact of interventions, or allocation of resources. Modelling studies are mostly based on epidemiological models, estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19, retrofits of crowd movement models to study occupant exposure, mobility-data based models to investigate transmission, or the use of macroeconomic models to assess the economic impact of the pandemic.
There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand. To minimise the harm from misinformation, medical professionals and the public are advised to expect rapid changes to available information, and to be attentive to retractions and other updates.
At least 29 Phase II–IV efficacy trials in COVID-19 were concluded in March 2020, or scheduled to provide results in April from hospitals in China. There are more than 300 active clinical trials underway as of April 2020. Seven trials were evaluating already approved treatments, including four studies on hydroxychloroquine or chloroquine. Repurposed antiviral drugs make up most of the research, with nine Phase III trials on remdesivir across several countries due to report by the end of April. Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.
The COVID-19 Clinical Research Coalition has goals to 1) facilitate rapid reviews of clinical trial proposals by ethics committees and national regulatory agencies, 2) fast-track approvals for the candidate therapeutic compounds, 3) ensure standardised and rapid analysis of emerging efficacy and safety data and 4) facilitate sharing of clinical trial outcomes before publication.
Several existing medications are being evaluated for the treatment of COVID-19, including remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta. There is tentative evidence for efficacy by remdesivir, and on 1 May 2020, the United States Food and Drug Administration (FDA) gave the drug an emergency use authorization (EUA) for people hospitalized with severe COVID-19. On 28 August 2020, the FDA broadened the EUA for remdesivir to include all hospitalized patients with suspected or laboratory-confirmed COVID-19, irrespective of the severity of their disease. Phase III clinical trials for several drugs[which?] are underway[when?] in several countries, including the US, China, and Italy.
There are mixed results as of 3 April 2020, as to the effectiveness of hydroxychloroquine as a treatment for COVID-19, with some studies showing little or no improvement. One study has shown an association between hydroxychloroquine or chloroquine use with higher death rates along with other side effects. A retraction of this study by its authors was published by The Lancet on 4 June 2020. The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study. On 15 June 2020, the FDA updated the fact sheets for the emergency use authorization of remdesivir to warn that using chloroquine or hydroxychloroquine with remdesivir may reduce the antiviral activity of remdesivir.
In June, initial results from a randomised trial in the United Kingdom showed that dexamethasone reduced mortality by one third for patients who are critically ill on ventilators and one fifth for those receiving supplemental oxygen. Because this is a well tested and widely available treatment this was welcomed by the WHO that is in the process of updating treatment guidelines to include dexamethasone or other steroids. Based on those preliminary results, dexamethasone treatment has been recommended by the National Institutes of Health for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID-19 who do not require supplemental oxygen.
In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence). The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID-19 patients.
In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents (from twelve years of age and weighing at least 40 kg) who require supplemental oxygen therapy. Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.
A cytokine storm can be a complication in the later stages of severe COVID-19. There is preliminary evidence that hydroxychloroquine may be useful in controlling cytokine storms in late-phase severe forms of the disease.
Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed. It is undergoing a Phase II non-randomised trial at the national level in Italy after showing positive results in people with severe disease. Combined with a serum ferritin blood test to identify a cytokine storm (also called cytokine storm syndrome, not to be confused with cytokine release syndrome), it is meant to counter such developments, which are thought to be the cause of death in some affected people. The interleukin-6 receptor antagonist was approved by the Food and Drug Administration (FDA) to undergo a Phase III clinical trial assessing its effectiveness on COVID-19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017. To date,[when?] there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no effect on the incidence of CRS.
Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID-19.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation. The safety and effectiveness of convalescent plasma as a treatment option requires further research. This strategy was tried for SARS with inconclusive results. Viral neutralization is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. The spike protein of SARS-CoV-2 is the primary target for neutralizing antibodies. As of 8 August 2020, eight neutralizing antibodies targeting the spike protein of SARS-CoV-2 have entered clinical studies. It has been proposed that selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV might be useful for treating not only COVID-19 but also future SARS-related CoV infections. Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible. Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development. Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
Peru announced in April 2020 that it would begin working towards creating a vaccine, with the pharmaceutical company Farvet and Universidad Peruana Cayetano Heredia (UPCH) announcing plans to jointly develop a vaccine in Chincha. Peru's Experimental Station for Scientific Research and Genetic Improvement of Alpacas belonging to the Inca Group, selected on 5 June 2020 four alpacas for the development of a new vaccine that it had been developing in conjunction with Farvet and UPCH. They also indicated that alpacas have the ability to generate some types of antibodies known as "nanobodies", which are very small and have a greater potential to treat pathogens. According to Andina, research from the United States, Belgium, and Chile showed that antibodies from laminoid animals could possibly be formulated into inhaler or injection treatments for those infected with coronaviruses, with Teodosio Huanca of Peru's National Institute of Agricultural Innovation (INIA) National Camelid Program stating that Peruvian camelidae share the same genetic roots and antibodies.
On 7 August, the Peruvian National Institute of Health (INS) announced that it would begin the development of a possible treatment for COVID-19 using "recombinant nanoantibodies" from a llama named "Tito". According to the INIA, Peru holds "the only germplasm bank of South American camelids in the world, with 1,700 samples of alpacas and 1,200 of llamas".
- COVID-19 pandemic
- Severe acute respiratory syndrome coronavirus 2, the virus that causes COVID-19
- Coronavirus diseases, a group of closely related syndromes
- Disease X, a WHO term
- Known as "close contact" which is variously defined, including within ~1.8 metres (six feet) by the US Centers for Disease Control and Prevention (CDC), and being face to face for at least 15 minutes, or sharing an enclosed space for a prolonged period such as 2 hours, by the Australian Health Department.
- "close contact" is defined as less than 1 metre (3.3 feet) by WHO and ECDC; and less than 1.8 metres (6 feet) by CDC.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (February 2020). "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet. 395 (10223): 507–513. doi:10.1016/S0140-6736(20)30211-7. PMC 7135076. PMID 32007143.
- Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. (March 2020). "Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery". Clinical Infectious Diseases. 71 (15): 723–731. doi:10.1093/cid/ciaa271. PMC 7184369. PMID 32227091.
- "Special Act for Prevention, Relief and Revitalization Measures for Severe Pneumonia with Novel Pathogens–Article Content–Laws & Regulations Database of The Republic of China". law.moj.gov.tw. Retrieved 10 May 2020.
- "Covid-19". Oxford English Dictionary (3rd ed.). Oxford University Press. April 2020. Retrieved 15 April 2020. (Subscription or UK public library membership required.)
- "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 13 May 2020. Archived from the original on 17 June 2020. Retrieved 18 June 2020.
- "Q&A on coronaviruses (COVID-19)". World Health Organization. 17 April 2020. Archived from the original on 14 May 2020. Retrieved 14 May 2020.
- Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al. (April 2020). "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review". The Cochrane Database of Systematic Reviews. 4: CD013574. doi:10.1002/14651858.CD013574. PMC 7141753. PMID 32267544.
- "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)". ArcGIS. Johns Hopkins University. Retrieved 20 October 2020.
- Smith, Dana G. "Coronavirus May Be a Blood Vessel Disease, Which Explains Everything". Medium. Retrieved 18 October 2020.
- "COVID-19 and vascular disease". EBioMedicine. 58: 102966. 2020. doi:10.1016/j.ebiom.2020.102966. PMC 7438984. PMID 32829782.
- "Coronavirus disease 2019 (COVID-19) – Symptoms and causes". Mayo Clinic. Retrieved 14 April 2020.
- "Q & A on COVID-19: Basic facts". www.ecdc.europa.eu. 25 September 2020. Retrieved 8 October 2020.
- Ye Q, Wang B, Mao J (June 2020). "The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19". The Journal of Infection. 80 (6): 607–613. doi:10.1016/j.jinf.2020.03.037. PMC 7194613. PMID 32283152.
- Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, et al. (September 2020). "Long-term consequences of COVID-19: research needs". The Lancet. Infectious Diseases. 20 (10): 1115–1117. doi:10.1016/S1473-3099(20)30701-5. PMC 7462626. PMID 32888409.
- "What are the long-term symptoms of COVID-19?". HMRI. 4 August 2020. Retrieved 8 September 2020.
- "COVID-19 (coronavirus): Long-term effects". Mayo Clinic. 18 August 2020. Retrieved 8 September 2020.
- "What are the long-term health risks following COVID-19?". NewsGP. Royal Australian College of General Practitioners (RACGP). 24 June 2020. Retrieved 8 September 2020.
- "Quarantine for coronavirus (COVID-19)". Australian Government Department of Health. Retrieved 25 September 2020.
- "How COVID-19 Spreads". U.S. Centers for Disease Control and Prevention (CDC). 18 September 2020. Archived from the original on 19 September 2020. Retrieved 20 September 2020.
- "Transmission of COVID-19". European Centre for Disease Prevention and Control. Retrieved 12 September 2020.
- "Q&A: How is COVID-19 transmitted?". World Health Organization (WHO). Retrieved 12 July 2020.
- "Transmission of SARS-CoV-2: implications for infection prevention precautions" (PDF). www.who.int. World Health Organization. 9 July 2020. Archived from the original on 9 July 2020. Retrieved 18 September 2020.
- Karia, R.; Gupta, I.; Khandait, H.; Yandav, A.; Yandav, A. (2020). "COVID-19 and its Modes of Transmission". SN Compr Clin Med. 2 (10): 1798–1801. doi:10.1007/s42399-020-00498-4. PMC 7461745. PMID 32904860. Retrieved 18 October 2020.
- "WHO Director-General's opening remarks at the media briefing on COVID-19". World Health Organization (WHO) (Press release). 11 March 2020. Archived from the original on 11 March 2020. Retrieved 12 March 2020.
- "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
- Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (23 June 2020). "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 15 (6): e0234765. Bibcode:2020PLoSO..1534765G. doi:10.1371/journal.pone.0234765. PMC 7310678. PMID 32574165. S2CID 220046286.
- "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 13 May 2020. Archived from the original on 17 June 2020. Retrieved 18 June 2020.
- "Coronavirus". World Health Organization (WHO). Retrieved 4 May 2020.
- "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 20 March 2020. Archived from the original on 30 January 2020.
- Gandhi RT, Lynch JB, Del Rio C (April 2020). "Mild or Moderate Covid-19". The New England Journal of Medicine. doi:10.1056/NEJMcp2009249. PMID 32329974.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (August 2020). "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 324 (8): 782–793. doi:10.1001/jama.2020.12839. PMID 32648899. S2CID 220465311.
- "COVID-19: epidemiology, virology and clinical features". GOV.UK. Retrieved 18 October 2020.
- "Q&A: How is COVID-19 transmitted? (How is the virus that causes COVID-19 most commonly transmitted between people?)". www.who.int. 9 July 2020. Retrieved 14 October 2020.
- "Transmission of COVID-19". www.ecdc.europa.eu. 7 September 2020. Retrieved 14 October 2020.
- "Frequently Asked Questions (Spread)". www.cdc.gov. 9 October 2020. Retrieved 14 October 2020.
- "Q&A: How is COVID-19 transmitted? (What do we know about aerosol transmission?)". www.who.int. 9 July 2020. Retrieved 14 October 2020.
- Jayaweera, M.; Perera, H.; Gunawardana, B.; Manatunge, J. (2020). "Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy". Environmental Research. 188: 109819. Bibcode:2020ER....188j9819J. doi:10.1016/j.envres.2020.109819. PMC 7293495. PMID 32569870.
- Kohanski, Michael A.; Lo, L. James; Waring, Michael S. (2020). "Review of indoor aerosol generation, transport, and control in the context of COVID-19". International Forum of Allergy & Rhinology. n/a (n/a). doi:10.1002/alr.22661. ISSN 2042-6984. PMC 7405119. PMID 32652898.
- "Transmission of SARS-CoV-2: implications for infection prevention precautions" (PDF). www.who.int. World Health Organization. 9 July 2020. Archived from the original on 9 July 2020. Retrieved 18 September 2020.
- "Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19" (PDF). www.who.int. 29 July 2020. Retrieved 14 October 2020.
- Meyerowitz, Eric A.; Richterman, Aaron; Gandhi, Rajesh T.; Sax, Paul E. (17 September 2020). "Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors". Annals of Internal Medicine. doi:10.7326/M20-5008. ISSN 0003-4819. PMID 32941052.
- "Q & A on COVID-19: Basic facts". www.ecdc.europa.eu. 25 September 2020. Retrieved 8 October 2020.
- "How COVID-19 Spreads". www.cdc.gov. 5 October 2020. Retrieved 7 October 2020.
- Liu, Tao; Gong, Dexin; Xiao, Jianpeng; Hu, Jianxiong; He, Guanhao; Rong, Zuhua; Ma, Wenjun. "Cluster infections play important roles in the rapid evolution of COVID-19 transmission: A systematic review". International Journal of Infectious Diseases. 99: 374–380. doi:10.1016/j.ijid.2020.07.073. ISSN 1201-9712. PMC 7405860. PMID 32768702.
- Herscher, Rebecca (12 October 2020). "Scientists Confirm Nevada Man Was Infected Twice With Coronavirus". NPR. Retrieved 12 October 2020.
- Tillet, Richard L.; et al. (12 October 2020). "Genomic evidence for reinfection with SARS-CoV-2: a case study". The Lancet. doi:10.1016/S1473-3099(20)30764-7. Retrieved 12 October 2020.
- "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China – fourth update" (PDF). European Centre for Disease Prevention and Control. 14 February 2020. Retrieved 8 March 2020.
- Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (April 2020). "The proximal origin of SARS-CoV-2". Nature Medicine. 26 (4): 450–452. doi:10.1038/s41591-020-0820-9. PMC 7095063. PMID 32284615.
- Gibbens S (18 March 2020). "Why soap is preferable to bleach in the fight against coronavirus". National Geographic. Archived from the original on 2 April 2020. Retrieved 2 April 2020.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (February 2020). "A Novel Coronavirus from Patients with Pneumonia in China, 2019". New England Journal of Medicine. 382 (8): 727–733. doi:10.1056/NEJMoa2001017. PMC 7092803. PMID 31978945.
- Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (PDF) (Report). World Health Organization (WHO). 24 February 2020. Archived (PDF) from the original on 29 February 2020. Retrieved 21 March 2020.
- Rathore, Jitendra Singh; Ghosh, Chaitali (25 August 2020). "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview". Pathogens and Disease. 78 (6). doi:10.1093/femspd/ftaa042. ISSN 2049-632X. OCLC 823140442. PMC 7499575. PMID 32840560.
- Thomas, Sunil. "The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET". Pathogens and Immunity. 5 (1): 342-363.
- "Coronavirus and COVID-19: What You Should Know". WebMD. Retrieved 31 July 2020.
- Verdecchia P, Cavallini C, Spanevello A, Angeli F (June 2020). "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection". European Journal of Internal Medicine. 76: 14–20. doi:10.1016/j.ejim.2020.04.037. PMC 7167588. PMID 32336612.
- Letko M, Marzi A, Munster V (April 2020). "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses". Nature Microbiology. 5 (4): 562–569. doi:10.1038/s41564-020-0688-y. PMC 7095430. PMID 32094589.
- Rodríguez‐Puertas, Rafael (2 September 2020). "ACE2 activators for the treatment of COVID 19 patients". Journal of Medical Virology. 92 (10): 1701–1702. doi:10.1002/jmv.25992. PMC 7267413. PMID 32379346.
- Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics". Drug Development Research. 81 (5): 537–540. doi:10.1002/ddr.21656. PMC 7228359. PMID 32129518.
- Gibson, Peter G; Qin, Ling; Puah, Ser Hon (1 April 2020). "COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS". The Medical Journal of Australia. 213 (2): 54–56.e1. doi:10.5694/mja2.50674. PMC 7361309. PMID 32572965.
- Li YC, Bai WZ, Hashikawa T (February 2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". Journal of Medical Virology. 92 (6): 552–555. doi:10.1002/jmv.25728. PMC 7228394. PMID 32104915.
- Baig AM, Khaleeq A, Ali U, Syeda H (April 2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. PMC 7094171. PMID 32167747.
- Yavarpour-Bali, Hanie; Ghasemi-Kasman, Maryam (1 September 2020). "Update on neurological manifestations of COVID-19". Life Sciences. 257: 118063. doi:10.1016/j.lfs.2020.118063. PMC 7346808. PMID 32652139.
- Gu J, Han B, Wang J (May 2020). "COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission". Gastroenterology. 158 (6): 1518–1519. doi:10.1053/j.gastro.2020.02.054. PMC 7130192. PMID 32142785.
- Zhang, Hui; Li, Hong-Bao; Lyu, Jian-Rui; Lei, Xiao-Ming; Li, Wei; Wu, Gang; Lyu, Jun; Dai, Zhi-Ming (2020). "Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection". International Journal of Infectious Diseases. Elsevier BV. 96: 19–24. doi:10.1016/j.ijid.2020.04.027. ISSN 1201-9712. PMC 7165079. PMID 32311451.
- Zheng YY, Ma YT, Zhang JY, Xie X (May 2020). "COVID-19 and the cardiovascular system". Nature Reviews. Cardiology. 17 (5): 259–260. doi:10.1038/s41569-020-0360-5. PMC 7095524. PMID 32139904.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (24 January 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223): 497–506. doi:10.1016/S0140-6736(20)30183-5. PMC 7159299. PMID 31986264.
- "Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues". UpToDate. Retrieved 28 September 2020.
- Turner AJ, Hiscox JA, Hooper NM (June 2004). "ACE2: from vasopeptidase to SARS virus receptor". Trends in Pharmacological Sciences. 25 (6): 291–4. doi:10.1016/j.tips.2004.04.001. PMC 7119032. PMID 15165741.
- Abou-Ismail, Mouhamed Yazan; Diamond, Akiva; Kapoor, Sargam; Arafah, Yasmin; Nayak, Lalitha (2 June 2020). "The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management". Thrombosis Research. Elsevier BV. 194: 101–115. doi:10.1016/j.thromres.2020.06.029. ISSN 0049-3848. PMC 7305763. PMID 32788101.
- Wadman M (April 2020). "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes". Science. doi:10.1126/science.abc3208.
- Coronavirus: Kidney Damage Caused by COVID-19, Johns Hopkins Medicine, C. John Sperati, updated 14 May 2020.
- Eketunde, Adenike O; Mellacheruvu, Sai priyanka; Oreoluwa, Philip (2 July 2020). "A Review of Postmortem Findings in Patients With COVID-19". Cureus. Cureus, Inc. 12 (7): e9438. doi:10.7759/cureus.9438. ISSN 2168-8184. PMC 7451084. PMID 32864262. S2CID 221352704.
- Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (March 2020). "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality". International Journal of Antimicrobial Agents. 55 (5): 105954. doi:10.1016/j.ijantimicag.2020.105954. PMC 7118634. PMID 32234467.
- Gómez-Rial, Jose; Rivero-Calle, Irene; Salas, Antonio; Martinón-Torres, Federico (2020). "Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy". Infection and Drug Resistance. 13: 2485–2493. doi:10.2147/IDR.S258639. PMC 7383015. PMID 32801787.
- "CDC Tests for 2019-nCoV". U.S. Centers for Disease Control and Prevention. 5 February 2020. Archived from the original on 14 February 2020. Retrieved 12 February 2020.
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". World Health Organization (WHO). Archived from the original on 17 March 2020. Retrieved 13 March 2020.
- "2019 Novel Coronavirus (2019-nCoV) Situation Summary". U.S. Centers for Disease Control and Prevention (CDC). 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
- "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 4 March 2020. Retrieved 26 March 2020.
- "Real-Time RT-PCR Panel for Detection 2019-nCoV". U.S. Centers for Disease Control and Prevention (CDC). 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
- "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
- Brueck H (30 January 2020). "There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus". Business Insider. Archived from the original on 1 February 2020. Retrieved 1 February 2020.
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases". Archived from the original on 21 February 2020. Retrieved 26 February 2020.
- Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264–266. doi:10.1016/j.ijid.2020.01.009. PMC 7128332. PMID 31953166.
- Cohen J, Normile D (January 2020). "New SARS-like virus in China triggers alarm" (PDF). Science. 367 (6475): 234–235. Bibcode:2020Sci...367..234C. doi:10.1126/science.367.6475.234. PMID 31949058. S2CID 210701594. Archived (PDF) from the original on 11 February 2020. Retrieved 11 February 2020.
- "Severe acute respiratory syndrome coronavirus 2 data hub". NCBI. Archived from the original on 21 March 2020. Retrieved 4 March 2020.
- Petherick A (April 2020). "Developing antibody tests for SARS-CoV-2". Lancet. 395 (10230): 1101–1102. doi:10.1016/s0140-6736(20)30788-1. PMC 7270070. PMID 32247384.
- Vogel G (March 2020). "New blood tests for antibodies could show true scale of coronavirus pandemic". Science. doi:10.1126/science.abb8028.
- Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. (February 2020). "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review". Journal of Clinical Medicine. 9 (3): 623. doi:10.3390/jcm9030623. PMC 7141113. PMID 32110875.
- Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. (June 2020). "Antibody tests for identification of current and past infection with SARS-CoV-2". The Cochrane Database of Systematic Reviews. 6: CD013652. doi:10.1002/14651858.CD013652. PMC 7387103. PMID 32584464. S2CID 220061130.
- AFP News Agency (11 April 2020). "How false negatives are complicating COVID-19 testing". Al Jazeera website Retrieved 12 April 2020.
- "Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic" (Press release). U.S. Food and Drug Administration (FDA). 21 March 2020. Archived from the original on 21 March 2020. Retrieved 22 March 2020.
- Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. (July 2020). "Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease". The Cochrane Database of Systematic Reviews. 7: CD013665. doi:10.1002/14651858.CD013665. PMC 7386785. PMID 32633856. S2CID 220384495.
- Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. (August 2020). "Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19". JAMA Internal Medicine. 180 (8): 1081–1089. doi:10.1001/jamainternmed.2020.2033. PMC 7218676. PMID 32396163.
- Levenfus I, Ullmann E, Battegay E, Schuurmans MM (August 2020). "Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score". The Brazilian Journal of Infectious Diseases: S1413867020301021. doi:10.1016/j.bjid.2020.07.003. PMC 7440000. PMID 32828735.
- Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (February 2020). "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)". Military Medical Research. 7 (1): 4. doi:10.1186/s40779-020-0233-6. PMC 7003341. PMID 32029004.
- To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JM, et al. (February 2020). "Consistent detection of 2019 novel coronavirus in saliva". Clinical Infectious Diseases. Oxford University Press. 71 (15): 841–843. doi:10.1093/cid/ciaa149. PMC 7108139. PMID 32047895.
- Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (March 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology. 215 (1): 87–93. doi:10.2214/AJR.20.23034. PMID 32174129.
- "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020. Archived from the original on 28 March 2020.
- Pormohammad, A; Ghorbani, S; Khatami, A; Razizadeh, MH; Alborzi, E; Zarei, M; Idrovo, JP; Turner, RJ (9 October 2020). "Comparison of influenza type A and B with COVID-19: A global systematic review and meta-analysis on clinical, laboratory and radiographic findings". Reviews in Medical Virology: e2179. doi:10.1002/rmv.2179. PMID 33035373. S2CID 222255245.
- Lee EY, Ng MY, Khong PL (April 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases. 20 (4): 384–385. doi:10.1016/S1473-3099(20)30134-1. PMC 7128449. PMID 32105641. Archived from the original on 8 March 2020. Retrieved 13 March 2020.
- "ICD-10 Version:2019". World Health Organization. 2019. Archived from the original on 31 March 2020. Retrieved 31 March 2020.
U07.2 – COVID-19, virus not identified – COVID-19 NOS – Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestations
- Giani M, Seminati D, Lucchini A, Foti G, Pagni F (May 2020). "Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe". Journal of Thoracic Oncology. 15 (5): e65–e66. doi:10.1016/j.jtho.2020.03.008. PMC 7118681. PMID 32194247.
- Lillicrap D (April 2020). "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia". Journal of Thrombosis and Haemostasis. 18 (4): 786–787. doi:10.1111/jth.14781. PMC 7166410. PMID 32212240.
- Mitra A, Dwyre DM, Schivo M, Thompson GR, Cohen SH, Ku N, Graff JP (March 2020). "Leukoerythroblastic reaction in a patient with COVID-19 infection". American Journal of Hematology. 95 (8): 999–1000. doi:10.1002/ajh.25793. PMC 7228283. PMID 32212392.
- Maier BF, Brockmann D (May 2020). "Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China". Science. 368 (6492): 742–746. Bibcode:2020Sci...368..742M. doi:10.1126/science.abb4557. PMC 7164388. PMID 32269067. ("...initial exponential growth expected for an unconstrained outbreak.")
- Wiles S (9 March 2020). "The three phases of Covid-19 – and how we can make it manageable". The Spinoff. Archived from the original on 27 March 2020. Retrieved 9 March 2020.
- Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (March 2020). "How will country-based mitigation measures influence the course of the COVID-19 epidemic?". Lancet. 395 (10228): 931–934. doi:10.1016/S0140-6736(20)30567-5. PMC 7158572. PMID 32164834.
A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
- Barclay E (10 March 2020). "How canceled events and self-quarantines save lives, in one chart". Vox. Archived from the original on 12 March 2020. Retrieved 12 March 2020.
- Barclay E, Scott D, Animashaun A (7 April 2020). "The US doesn't just need to flatten the curve. It needs to "raise the line."". Vox. Archived from the original on 7 April 2020.
- Wiles S (14 March 2020). "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means". The Spinoff. Archived from the original on 26 March 2020. Retrieved 13 March 2020.
- Grenfell R, Drew T (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". Science Alert. Archived from the original on 28 February 2020. Retrieved 26 February 2020.
- "COVID-19 Treatment Guidelines". www.nih.gov. National Institutes of Health. Retrieved 21 April 2020.
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (April 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 323 (18): 1824–1836. doi:10.1001/jama.2020.6019. PMID 32282022.
- "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 28 June 2020.
- Centers for Disease Control and Prevention (3 February 2020). "Coronavirus Disease 2019 (COVID-19): Prevention & Treatment". Archived from the original on 15 December 2019. Retrieved 10 February 2020.
- World Health Organization. "Advice for Public". Archived from the original on 26 January 2020. Retrieved 10 February 2020.
- "My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub". NPR.org. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
- Centers for Disease Control and Prevention (5 April 2020). "What to Do if You Are Sick". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 14 February 2020. Retrieved 24 April 2020.
- "Coronavirus Disease 2019 (COVID-19) – Prevention & Treatment". U.S. Centers for Disease Control and Prevention (CDC). 10 March 2020. Archived from the original on 11 March 2020. Retrieved 11 March 2020.
- Verbeek JH, Rajamaki B, Ijaz S, Sauni R, Toomey E, Blackwood B, et al. (May 2020). "Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff". The Cochrane Database of Systematic Reviews. 5: CD011621. doi:10.1002/14651858.CD011621.pub5. PMID 32412096.
- "Wear masks in public says WHO, in update of COVID-19 advice". Reuters. 5 June 2020. Retrieved 3 July 2020.
- "Recommendations for Cloth Face Covers". U.S. Centers for Disease Control and Prevention (CDC). 3 April 2020. Retrieved 3 June 2020.
- "When and how to use masks". WHO. Retrieved 3 July 2020.
- "Social distancing: what you need to do – Coronavirus (COVID-19)". nhs.uk. 2 June 2020. Retrieved 18 August 2020.
- "COVID-19: Use of masks in the community". Ministry of Health NZ. Retrieved 18 August 2020.
- "Using face masks in the community – Technical Report" (PDF). ECDC. 8 April 2020.
- "Which countries have made wearing face masks compulsory?". Al Jazeera. 20 May 2020.
- "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 17 April 2020.
- "For different groups of people: how to choose masks". NHC.gov.cn. National Health Commission of the People's Republic of China. 7 February 2020. Retrieved 22 March 2020.
Disposable medical masks: Recommended for: • People in crowded places • Indoor working environment with a relatively dense population • People going to medical institutions • Children in kindergarten and students at school gathering to study and do other activities
- Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L (April 2020). "Face masks for the public during the covid-19 crisis". BMJ. 369: m1435. doi:10.1136/bmj.m1435. PMID 32273267. S2CID 215516381.
- "Caring for Someone Sick at Home". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 3 July 2020.
- Maragakis LL. "Coronavirus, Social Distancing and Self Quarantine". www.hopkinsmedicine.org. Johns Hopkins University. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
- Parker-Pope T (19 March 2020). "Deciding How Much Distance You Should Keep". The New York Times. ISSN 0362-4331. Archived from the original on 20 March 2020. Retrieved 20 March 2020.
- Systrom K, Krieger M, O'Rourke R, Stein R, Dellaert F, Lerer A (11 April 2020). "Rt Covid-19". rt.live. Retrieved 19 April 2020. Based on Bettencourt LM, Ribeiro RM (May 2008). "Real time bayesian estimation of the epidemic potential of emerging infectious diseases". PLOS ONE. 3 (5): e2185. Bibcode:2008PLoSO...3.2185B. doi:10.1371/journal.pone.0002185. PMC 2366072. PMID 18478118.
- "Advice for the public on COVID-19 – World Health Organization". www.who.int. Retrieved 18 August 2020.
- "WHO-recommended handrub formulations". WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization. 19 March 2009. Retrieved 19 March 2020.
- "List N: Disinfectants for Use Against SARS-CoV-2 (COVID-19)". US EPA. 13 March 2020.
- Fisher D, Heymann D (February 2020). "Q&A: The novel coronavirus outbreak causing COVID-19". BMC Medicine. 18 (1): 57. doi:10.1186/s12916-020-01533-w. PMC 7047369. PMID 32106852.
- Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (May 2020). "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province". Chinese Medical Journal. 133 (9): 1025–1031. doi:10.1097/CM9.0000000000000744. PMC 7147277. PMID 32044814.
- Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (March 2020). "Comorbidities and multi-organ injuries in the treatment of COVID-19". Lancet. 395 (10228): e52. doi:10.1016/s0140-6736(20)30558-4. PMC 7270177. PMID 32171074.
- Henry BM (April 2020). "COVID-19, ECMO, and lymphopenia: a word of caution". The Lancet. Respiratory Medicine. 8 (4): e24. doi:10.1016/s2213-2600(20)30119-3. PMC 7118650. PMID 32178774.
- Wang L, Wang Y, Ye D, Liu Q (March 2020). "Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence". International Journal of Antimicrobial Agents. 55 (6): 105948. doi:10.1016/j.ijantimicag.2020.105948. PMC 7156162. PMID 32201353. Archived from the original on 27 March 2020. Retrieved 27 March 2020.
- Wang Y, Wang Y, Chen Y, Qin Q (March 2020). "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures". Journal of Medical Virology. n/a (n/a): 568–576. doi:10.1002/jmv.25748. PMC 7228347. PMID 32134116.
- Cheng ZJ, Shan J (April 2020). "2019 Novel coronavirus: where we are and what we know". Infection. 48 (2): 155–163. doi:10.1007/s15010-020-01401-y. PMC 7095345. PMID 32072569.
- "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected". World Health Organization (WHO). Archived from the original on 31 January 2020. Retrieved 13 February 2020.
- Farkas J (March 2020). COVID-19 – The Internet Book of Critical Care (digital) (Reference manual). USA: EMCrit. Archived from the original on 11 March 2020. Retrieved 13 March 2020.
- "COVID19 – Resources for Health Care Professionals". Penn Libraries. 11 March 2020. Archived from the original on 14 March 2020. Retrieved 13 March 2020.
- Roser M, Ritchie H, Ortiz-Ospina E (4 March 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Archived from the original on 19 March 2020. Retrieved 12 March 2020.
- Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 February 2020). "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China, 2020". China CDC Weekly. Chinese Center for Disease Control and Prevention. 2 (8): 113–122. doi:10.46234/ccdcw2020.032. Archived from the original on 19 February 2020. Retrieved 18 March 2020.
- 코로나바이러스감염증-19 국내 발생 현황(7월 17일, 정례브리핑) (Report) (in Korean). Korea Centers for Disease Control and Prevention. 17 July 2020. Retrieved 17 July 2020.
- Actualización nº 109. Enfermedad por el coronavirus (COVID-19) (PDF) (Report) (in Spanish). Ministerio de Sanidad, Consumo y Bienestar Social. 18 May 2020. Retrieved 20 May 2020.
- "Epidemia COVID-19 – Bollettino sorveglianza integrata COVID-19" (PDF) (in Italian). Istituto Superiore di Sanità. 5 June 2020. Retrieved 10 June 2020.
- Roser M, Ritchie H, Ortiz-Ospina E (6 April 2020). "Coronavirus Disease (COVID-19)". Our World in Data. Retrieved 6 April 2020.
- Palmieri L, Andrianou X, Barbariol P, Bella A, Bellino S, Benelli E, et al. (22 July 2020). Characteristics of SARS-CoV-2 patients dying in Italy Report based on available data on July 22nd, 2020 (PDF) (Report). Istituto Superiore di Sanità. Retrieved 4 October 2020.
- Vardavas CI, Nikitara K (20 March 2020). "COVID-19 and smoking: A systematic review of the evidence". Tobacco Induced Diseases. 18 (March): 20. doi:10.18332/tid/119324. PMC 7083240. PMID 32206052.
- Engin AB, Engin ED, Engin A (August 2020). "Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking". Environmental Toxicology and Pharmacology. 78: 103411. doi:10.1016/j.etap.2020.103411. PMC 7227557. PMID 32422280.
- COVID-19: Who's at higher risk of serious symptoms?
- Tamara A, Tahapary DL (1 July 2020). "Obesity as a predictor for a poor prognosis of COVID-19: A systematic review". Diabetes & Metabolic Syndrome. 14 (4): 655–659. doi:10.1016/j.dsx.2020.05.020. PMC 7217103. PMID 32438328.
- Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. (July 2020). "Obesity – a risk factor for increased COVID-19 prevalence, severity and lethality (Review)". Molecular Medicine Reports. 22 (1): 9–19. doi:10.3892/mmr.2020.11127. PMC 7248467. PMID 32377709.
- If you are immunocompromised, protect yourself from COVID-19
- COVID-19 infection in kidney transplant recipients
- John Parkinson (25 June 2020). "Study: Majority of Children with COVID-19 Have Mild Disease, Mortality is Rare". ContagionLive.
- Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. (April 2020). "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review". JAMA Pediatrics. doi:10.1001/jamapediatrics.2020.1467. PMID 32320004.
- Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. (April 2020). "SARS-CoV-2 Infection in Children". The New England Journal of Medicine. Massachusetts Medical Society. 382 (17): 1663–1665. doi:10.1056/nejmc2005073. PMC 7121177. PMID 32187458.
- Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (June 2020). "Epidemiology of COVID-19 Among Children in China" (PDF). Pediatrics. 145 (6): e20200702. doi:10.1542/peds.2020-0702. PMID 32179660. S2CID 219118986. Archived (PDF) from the original on 17 March 2020. Retrieved 16 March 2020.
- CDC (11 February 2020). "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. Retrieved 10 October 2020.
- "Misleading claim circulates online about infection fatality ratio of Covid-19 in the US". Fact Check. 8 October 2020. Retrieved 10 October 2020.
- One in Seven Dire COVID Cases May Result from a Faulty Immune Response
- Auto-antibodies against type I IFNs in patients with life-threatening COVID-19
- A Genetic Screen Identifies Interferon-α Effector Genes Required to Suppress Hepatitis C Virus Replication
- Fang L, Karakiulakis G, Roth M (April 2020). "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?". The Lancet. Respiratory Medicine. 8 (4): e21. doi:10.1016/S0140-6736(20)30311-1. PMC 7118626. PMID 32171062.
- "Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Archived from the original on 2 March 2020. Retrieved 2 March 2020.
- "Sala de Situación COVID-19 Nuevo Coronavirus 2019 Novedades al 07/05 - 18 hs- SE 19" (PDF) (in Spanish). 7 May 2020.
- Health, Australian Government Department of (4 June 2020). "COVID-19 cases by age group and sex". Australian Government Department of Health. Retrieved 4 June 2020. Health, Australian Government Department of (4 June 2020). "COVID-19 deaths by age group and sex". Australian Government Department of Health. Retrieved 4 June 2020.
- "Coronavirus Disease 2019 (COVID-19) DAILY EPIDEMIOLOGY UPDATE Updated: 3 June, 2020, 11:00 AM ET" (PDF). Public Health Agency of Canada. 3 June 2020. Retrieved 4 June 2020.
- "COVID-19 Alberta statistics". Government of Alberta.
- "British Columbia COVID-19 Daily Situation Report, June 3, 2020" (PDF). BC Centre for Disease Control.
- "Ontario COVID-19 Data Tool". Public Health Ontario.
- "Situation of the coronavirus (COVID-19) in Québec". www.quebec.ca.
- "22° informe epidemiológico COVID-19". Ministerio de Salud – Gobierno de Chile.
- Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 February 2020). "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China, 2020". China CDC Weekly. Chinese Center for Disease Control and Prevention. 2 (8): 113–122. Archived from the original on 19 February 2020. Retrieved 18 March 2020.
- "Coronavirus Colombia". www.ins.gov.co.
- Overvågning af COVID-19 (Report) (in Danish). Statens Serum Institut. 4 June 2020. Retrieved 4 June 2020.
- "Confirmed coronavirus cases (COVID-19) in Finland". experience.arcgis.com. THL. "Tilannekatsaus koronaviruksesta - Infektiotaudit ja rokotukset - THL". Terveyden ja hyvinvoinnin laitos.
- "Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the Robert Koch Institute 05/06/2020 - UPDATED STATUS FOR GERMANY" (PDF). Robert Koch Institute.
- "קורונה - משרד הבריאות". Ministry of Health (Israel). 3 May 2020. Retrieved 5 May 2020.
- "Integrated surveillance of COVID-19 in Italy" (PDF). Istituto Superiore di Sanità.
- "Coronavirus Disease (COVID-19) Situation Report in Japan". toyokeizai.net.
- COVID-19 Tablero México - CONACYT (Report) (in Spanish). Mexico City: CONACYT. 3 June 2020. Retrieved 4 June 2020.
- Epidemiologische situatie COVID-19 in Nederland 3 juni 2020 (Report) (in Dutch). Bilthoven: Rijksinstituut voor Volksgezondheid en Milie. 4 June 2020. Retrieved 4 June 2020.
- "COVID-19 Dagsrapport fredag 4. juni 2020" (PDF). Folkehelseinstituttet. 4 June 2020. Retrieved 4 June 2020.
- "COVID-19 Tracker | Department of Health website". Doh.gov.ph. 4 June 2020. Retrieved 4 June 2020.
- "NOVO CORONAVÍRUS COVID-19 RELATÓRIO DE SITUAÇÃO" (PDF) (in Portuguese). 4 June 2020. Retrieved 4 June 2020.